MedTrace Logo

The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor

NCT02166515 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2014-06-18

No results posted yet for this study

Summary

As human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. Ovarian, cervical and endometrial cancer are three major gynecological malignancies. In recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising.

The key to gynecologic malignancies is how to early diagnose and treat. With the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. Genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. Therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.

Conditions

  • Gynecologic Malignant Tumor

Sponsors & Collaborators

  • Shenzhen Huada Genomics Co., Ltd.

    collaborator UNKNOWN

  • Zhiqing, Liang

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-10-31
Completion
2017-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02166515 on ClinicalTrials.gov